BACKGROUND: Intermittent preventive treatment aims to maximize the protective effects of malaria chemoprophylaxis while minimizing the deleterious effects. METHODS: In Gabon, 1189 infants received either sulfadoxine-pyrimethamine (SP; 250 and 12.5 mg, respectively) or placebo at 3, 9, and 15 months of age. Children were actively followed-up until 18 months of age. RESULTS: In the intention-to-treat population at 18 months of follow-up, 84 children (17%) in the SP group had > or =1 episode of anemia, versus 108 (21%) in the placebo group (protective efficacy, 22% [95% confidence interval {CI}, -1% to 40%]; P=.06). In the intervention group, there were 66 episodes during 485 person-years at risk, compared with 79 episodes during 497 years in the placebo group (protective efficacy, 17% [95% CI, -24% to 45%; P=.36). The effects were similar at 12 months of follow-up. The study drug was safe and well tolerated. CONCLUSIONS: The intervention was efficacious, producing a reduction in risk for anemia but a smaller effect against malaria. It is a valuable additional tool to control malaria in a highly vulnerable age group. Remaining important questions are currently being addressed in further studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00167843.
RCT Entities:
BACKGROUND: Intermittent preventive treatment aims to maximize the protective effects of malaria chemoprophylaxis while minimizing the deleterious effects. METHODS: In Gabon, 1189 infants received either sulfadoxine-pyrimethamine (SP; 250 and 12.5 mg, respectively) or placebo at 3, 9, and 15 months of age. Children were actively followed-up until 18 months of age. RESULTS: In the intention-to-treat population at 18 months of follow-up, 84 children (17%) in the SP group had > or =1 episode of anemia, versus 108 (21%) in the placebo group (protective efficacy, 22% [95% confidence interval {CI}, -1% to 40%]; P=.06). In the intervention group, there were 66 episodes during 485 person-years at risk, compared with 79 episodes during 497 years in the placebo group (protective efficacy, 17% [95% CI, -24% to 45%; P=.36). The effects were similar at 12 months of follow-up. The study drug was safe and well tolerated. CONCLUSIONS: The intervention was efficacious, producing a reduction in risk for anemia but a smaller effect against malaria. It is a valuable additional tool to control malaria in a highly vulnerable age group. Remaining important questions are currently being addressed in further studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00167843.
Authors: Ilona Carneiro; Lucy Smith; Amanda Ross; Arantxa Roca-Feltrer; Brian Greenwood; Joanna Armstrong Schellenberg; Thomas Smith; David Schellenberg Journal: Bull World Health Organ Date: 2010-05-10 Impact factor: 9.408
Authors: Matthew Cairns; Roly Gosling; Ilona Carneiro; Samwel Gesase; Jacklin F Mosha; Ramadhan Hashim; Harparkash Kaur; Martha Lemnge; Frank W Mosha; Brian Greenwood; Daniel Chandramohan Journal: PLoS One Date: 2010-03-01 Impact factor: 3.240
Authors: Lesong Conteh; Elisa Sicuri; Fatuma Manzi; Guy Hutton; Benson Obonyo; Fabrizio Tediosi; Prosper Biao; Paul Masika; Fred Matovu; Peter Otieno; Roly D Gosling; Mary Hamel; Frank O Odhiambo; Martin P Grobusch; Peter G Kremsner; Daniel Chandramohan; John J Aponte; Andrea Egan; David Schellenberg; Eusebio Macete; Laurence Slutsker; Robert D Newman; Pedro Alonso; Clara Menéndez; Marcel Tanner Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240
Authors: Marjolein Gysels; Christopher Pell; Don P Mathanga; Philip Adongo; Frank Odhiambo; Roly Gosling; Patricia Akweongo; Rose Mwangi; George Okello; Peter Mangesho; Lawrence Slutsker; Peter G Kremsner; Martin P Grobusch; Mary J Hamel; Robert D Newman; Robert Pool Journal: Malar J Date: 2009-08-10 Impact factor: 2.979
Authors: Mayke J A M Oesterholt; Michael Alifrangis; Colin J Sutherland; Sabah A Omar; Patrick Sawa; Christina Howitt; Louis C Gouagna; Robert W Sauerwein; Teun Bousema Journal: PLoS One Date: 2009-02-05 Impact factor: 3.240